

The OVA1® plus report with OVERA® reflex helps you get a better assessment of cancer risk when managing pelvic masses.

OVERA® Score

The OVERA® Score is displayed with the status indicating Low or Elevated Malignancy Risk.

Patient Info Last Name: XXXXXXXXXXXXXXXXXXXX First Name: MRN: DOB: Age: Gender: Ethnicity:	Ordering Provider: Practice Name Street Address City, State, Zip Tel: Fax: Copy-to-Physician: Fax:	Laboratory Info Accession No: Client No: Collection Date: Received Date: Final Report Date:
--	--	---

Clinical Information: ? Ultrasound Results Unknown **Menopausal Status:** Premenopausal

Test Name	Result	Status	Reference Range
	4.0	Low Risk	Low Risk < 5.0 Elevated Risk ≥ 5.0
	5.0	Reflex	Premenopausal Reflex Range 5.0-7.0

Interpretation:
 A **LOW RISK OVA1** results in a Risk of Malignancy of 1%, or 2% when combined with ultrasound results (see below). Results should be interpreted along with clinical and ultrasound assessment. A low risk value has been determined to have a negative predictive value of 98%.

Providing Menopausal status and Ultrasound results helps to narrow down the risk of Malignancy

Risk of Malignancy: 1.5% (premenopausal, **low risk** ultrasound)
 or
Risk of Malignancy: 2.0% (premenopausal, **high risk** ultrasound)

*Risk of Malignancy is a combination of the OVERA Result, Menopausal status and Ultrasound results

Test Name	Result	Status	Reference Range
Epithelial Tumor Markers			
CA-125 II	10.0 U/mL	Normal Range	Premenopausal ≤ 63.0 U/mL
HE4	23.0 pmol/L	Normal Range	Premenopausal ≤ 63.6 pmol/L
Epithelial Tumor Markers (Mucinous type)			
CA 19.9	15.0 U/mL	Normal Range	≤ 35.0 U/mL
CEA	3.0 ng/mL	Normal Range	Non Smokers < 5.0 ng/mL Smokers < 6.5 ng/mL

Interpretation: Results in the normal range may suggest low risk for ovarian cancer. Epithelial-Cell Tumors make up an average of 75% of all ovarian cancer tumor types, including serous, mucinous, endometrioid, clear cell, and Brenner tumors.

www.aspirawh.com
 12117 Bee Caves Road Building III, Ste 100
 Austin, Texas 78738

aspirasupport@aspirawh.com
 P 1-844-ASPIRA1
 F 1-866-283-3634

CLIA Lab No: 45D2073394
 NYSDOH: 8885
 Herbert Fritsche, Ph.D.
 Laboratory Director

Page 1 of 2
 PRC000XXXXX
 © 2020, ASPIRA Labs

CA-125

CA-125 is included in the panel of five biomarkers in OVERA® and will be included on the OVA1® results report.

Additional Biomarkers

Additional Biomarkers, if ordered, will be reported here with a personalized interpretation.

Risk of Malignancy

This table shows the Risk of Malignancy combining, ultrasound, menopausal status and OVERA® value. The higher the score the greater risk of malignancy.